Literature DB >> 34296397

Association Between Vitamin D and Statin-Related Myopathy: A Meta-analysis.

Qingtao Hou1, Caishuang Pang2, Yuqin Chen3.   

Abstract

BACKGROUND: Myopathy is the most widely reported statin-associated adverse event. Several studies have linked vitamin D deficiency with statin-related myopathy.
OBJECTIVE: This meta-analysis aimed to investigate whether adult patients with statin-related myopathy have a lower 25-hydroxyvitamin D (25OHD) level than patients without myopathy and whether statin-related myopathy in vitamin D-deficient patients can be improved by vitamin D supplementation.
METHODS: PubMed, EMBASE, and the Cochrane Central Register of Controlled Trials were searched until 28 September 2020. Original studies comparing the 25OHD levels of patients with and without myopathy or detecting the impact of vitamin D supplementation on statin-related muscular intolerance were included. Subgroup analyses based on the sample size and baseline 25OHD level were conducted.
RESULTS: This meta-analysis, based on nine cohort studies with a total of 2906 patients, revealed that the 25OHD level of patients with statin-related myopathy was significantly lower than that of patients without myopathy [weighted mean difference - 4.17 ng/mL; 95% confidence interval (CI) - 7.70 to - 0.63; p = 0.021]. The overall analysis from another four studies with 446 patients who were previously vitamin D deficient and reported statin-related muscular intolerance showed that the pooled tolerance rate of statins improved to 89% (95% CI 8692; p < 0.001) after vitamin D supplementation.
CONCLUSIONS: The present meta-analysis provides evidence that low 25OHD level is associated with statin-related myopathy and that exogenous vitamin D supplementation can improve statin-related muscular intolerance associated with low 25OHD level in most cases. Our findings may provide useful insight for the prevention and treatment of statin-related myopathy.
© 2021. The Author(s), under exclusive licence to Springer Nature Switzerland AG.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34296397     DOI: 10.1007/s40256-021-00492-8

Source DB:  PubMed          Journal:  Am J Cardiovasc Drugs        ISSN: 1175-3277            Impact factor:   3.571


  3 in total

1.  2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.

Authors:  Neil J Stone; Jennifer G Robinson; Alice H Lichtenstein; C Noel Bairey Merz; Conrad B Blum; Robert H Eckel; Anne C Goldberg; David Gordon; Daniel Levy; Donald M Lloyd-Jones; Patrick McBride; J Sanford Schwartz; Susan T Shero; Sidney C Smith; Karol Watson; Peter W F Wilson; Karen M Eddleman; Nicole M Jarrett; Ken LaBresh; Lev Nevo; Janusz Wnek; Jeffrey L Anderson; Jonathan L Halperin; Nancy M Albert; Biykem Bozkurt; Ralph G Brindis; Lesley H Curtis; David DeMets; Judith S Hochman; Richard J Kovacs; E Magnus Ohman; Susan J Pressler; Frank W Sellke; Win-Kuang Shen; Sidney C Smith; Gordon F Tomaselli
Journal:  Circulation       Date:  2013-11-12       Impact factor: 29.690

2.  Low plasma vitamin D levels and muscle-related adverse effects in statin users.

Authors:  Alon Eisen; Eli Lev; Zaza Iakobishvilli; Avital Porter; David Brosh; David Hasdai; Aviv Mager
Journal:  Isr Med Assoc J       Date:  2014-01       Impact factor: 0.892

3.  Impact of vitamin D status on statin-induced myopathy.

Authors:  Krista D Riche; Justin Arnall; Kristin Rieser; Honey E East; Daniel M Riche
Journal:  J Clin Transl Endocrinol       Date:  2016-11-23
  3 in total
  2 in total

1.  Association Between Vitamin D Supplementation and Statin-Associated Muscle Symptoms: A Systematic Review.

Authors:  Chong Boon Teo; Pek Yan Tan; Ryan Yong Kiat Tay; Joan Khoo; Gerald F Watts; Wann Jia Loh
Journal:  High Blood Press Cardiovasc Prev       Date:  2022-06-29

Review 2.  Statins Neuromuscular Adverse Effects.

Authors:  Silvia Attardo; Olimpia Musumeci; Daniele Velardo; Antonio Toscano
Journal:  Int J Mol Sci       Date:  2022-07-28       Impact factor: 6.208

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.